Lapatinib and Radiation Therapy in Treating Patients With Locally Recurrent or Chemotherapy-Refractory Locally Advanced or Metastatic Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

June 30, 2010

Study Completion Date

August 31, 2012

Conditions
Breast Cancer
Interventions
DRUG

lapatinib ditosylate

Patients will be assigned in cohorts of 3. Dose levels of GW572106 will include 500mg, 1000mg,1500 mg (additional levels at 750 mg and 1250 mg will be added if needed). Lapatinib is an oral drug. It is taken every day.

GENETIC

TdT-mediated dUTP nick end labeling assay

Genetic analysis of tumor tissue

GENETIC

gene expression analysis

Genetic analysis of tumor tissue.

GENETIC

microarray analysis

Genetic analysis of tumor tissue.

OTHER

immunohistochemistry staining method

Laboratory analysis of tumor tissue.

PROCEDURE

biopsy

Serial biopsies by skin punch or core biopsy or fine needle aspiration.

RADIATION

radiation therapy

Radiotherapy will be delivered at standard dose and fractionation. For patients who have not received previous locoregional radiotherapy, 50-56 Gy will be delivered to the regional lymph nodes and/or chest wall at a dose of 2 Gy per fraction, 5 days per week followed by a boost to the sites of gross involvement to a total dose of 60-70 Gy over a course of 6-7 weeks. For patients who have received adjuvant radiotherapy, a dose of 35-45 Gy will be delivered to sites of chest wall involvement at a dose of 1.8 Gy per fraction over 4-5 weeks. In either de novo or reirradiated settings, the total dose to the brachial plexus will not exceed 60 Gy.

Trial Locations (1)

27599-7295

Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

UNC Lineberger Comprehensive Cancer Center

OTHER

NCT00379509 - Lapatinib and Radiation Therapy in Treating Patients With Locally Recurrent or Chemotherapy-Refractory Locally Advanced or Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter